Allied with Genentech and Pfizer on discovery deals, protein degradation crew at Arvinas looks for $100M IPO ahead of PhI start
The next wave of biotech IPOs is starting to swell today as the protein degradation crew at Arvinas jumps in with a $100 million offering. And once again we’re seeing a discovery company going early — with their first Phase I program still out ahead.
Arvinas gained a considerable amount of attention for two deals with Genentech and Pfizer, which we now know came with a relatively small upfront and big back end numbers.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
